FY2029 Earnings Estimate for IPSC Issued By Leerink Partnrs

Century Therapeutics, Inc. (NASDAQ:IPSC) – Research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for Century Therapeutics in a report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings per share of ($1.18) for the year. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.63) per share.

A number of other equities analysts have also recently commented on the company. Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. Chardan Capital reduced their price target on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Piper Sandler reduced their price objective on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a report on Monday, December 30th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday, January 22nd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $10.00.

Century Therapeutics Stock Performance

Century Therapeutics stock opened at $0.77 on Friday. Century Therapeutics has a 52 week low of $0.68 and a 52 week high of $5.51. The stock has a market capitalization of $65.86 million, a P/E ratio of -0.42 and a beta of 1.73. The stock has a 50-day simple moving average of $0.98 and a 200 day simple moving average of $1.36.

Institutional Investors Weigh In On Century Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in IPSC. Renaissance Technologies LLC raised its position in shares of Century Therapeutics by 146.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock valued at $1,215,000 after buying an additional 714,685 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Century Therapeutics in the third quarter valued at approximately $284,000. JPMorgan Chase & Co. raised its position in shares of Century Therapeutics by 127.5% in the fourth quarter. JPMorgan Chase & Co. now owns 163,189 shares of the company’s stock valued at $165,000 after buying an additional 91,468 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Century Therapeutics in the fourth quarter valued at approximately $87,000. Finally, State Street Corp raised its position in shares of Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after buying an additional 57,323 shares in the last quarter. 50.20% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.